The firm will work with investigators from the University of North Carolina at Chapel Hill and the University of Virginia to validate its AIR system in CRISPR workflows.
The Seattle-based firm's PickSeq platform integrates cell imaging and extraction tools for downstream RNA enrichment, sequencing, and targeted biomarker discovery.
The firm said that the technology contains an enclosed, sterile sorting chip that enables users to type cells according to biomarkers and sort them into separate outputs.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The SciLifeLab spinout uses barcoded probes, in situ rolling circle amplification, and sequencing by ligation to measure expression of a panel of genes.
The platform, from a University of Illinois at Chicago-led team, separates circulating tumor cells from other cell types using size-dependent inertial migration.
The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
SeqOnce, which was founded in 2014, has developed a technology for NGS library preparation that it says is significantly quicker than competing methods.
Twist continues to invest in NGS while growing its core synthetic biology business, and has filed a countercomplaint in its ongoing litigation with Agilent.
Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.
